TUSTIN, CA--(Marketwire - February 26, 2013) -
| Highlighted Links |
|
|
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will participate at the following investor conferences:
-
33rd Annual Cowen Health Care Conference
Tuesday, March 5, 2013, at 10:40am Eastern Standard Time
Marriott Copley Hotel Boston, Massachusetts -
25th Annual ROTH Conference
Monday, March 18, 2013, at 2:00pm Pacific Daylight Time
The Ritz Carlton Hotel Dana Point, California - Stifel Nicolaus & Company Biotechnology Investor Day
Wednesday, March 20, 2013
San Francisco, California
Peregrine’s presentations at the Cowen and Roth Conferences will be webcast live and available for replay until April 12, 2013 and April 25, 2013, respectively at: http://ir.peregrineinc.com/events.cfm.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
